[Translation] A prospective, randomized, controlled, open-label, multicenter trial evaluating the efficacy, safety, and patient-reported outcomes of 177Lu-edotreotide peptide receptor radionuclide therapy (PRRT) compared with best standard therapy in patients with well-differentiated aggressive grade 2 and 3 somatostatin receptor-positive (SSTR+) neuroendocrine tumors of gastrointestinal or pancreatic origin (COMPOSE)

在高分化侵袭性2级（G2）和3级（G3）GEP-NETs患者中确认177Lu-依多曲肽PRRT的有效性和安全性

[Translation]

To confirm the efficacy and safety of 177Lu-edotreotide PRRT in patients with well-differentiated aggressive grade 2 (G2) and grade 3 (G3) GEP-NETs

Start Date11 Feb 2025

Sponsor / Collaborator

ITM Solucin GmbH

[+1]

NCT06441331

/ Not yet recruitingPhase 1

A Multicenter, Open-label, Interventional Phase I Trial to Determine the Dose and Evaluate the Pharmacokinetics (PK) and Safety of Lutetium Lu 177 Edotreotide Targeted Radiopharmaceutical Therapy (RPT) as Monotherapy or Following Standard of Care (SoC) for the Treatment of Somatostatin Receptor-positive Tumors in the Pediatric Population (KinLET).

The purpose of the study is to determine the appropriate pediatric dosage and evaluate the pharmacokinetics (PK) and safety of Lutetium Lu 177 Edotreotide Targeted Radiopharmaceutical Therapy (RPT) as a monotherapy or following standard of care (SoC) in participants ≥2 to <18 years of age with somatostatin receptor (SSTR)-positive tumors.

Start Date01 Jan 2025

Sponsor / Collaborator

ITM Solucin GmbH

NCT05918302

/ RecruitingPhase 3IIT

Efficacy, Safety and Patient-reported Outcomes of Peptide Receptor Radionuclide Therapy with 177Lu-edotreotide Compared to Everolimus in Somatostatin Receptor Positive Neuroendocrine Tumors of the Lung and Thymus.

LEVEL trial aims to demonstrate the higher efficacy of 177Lu-edotreotide over everolimus in patients with well to moderately differentiated neuroendocrine tumors of the lung and thymus who require systemic therapy. It is hypothesized that 177Lu-edotreotide may significantly increase the progression-free survival (PFS) compared to everolimus in lung and thymic carcinoids.

Start Date27 Oct 2023

Sponsor / Collaborator

Itm Isotope Technologies Munich SE

100 Clinical Results associated with Lutetium (177Lu) edotreotide

100 Translational Medicine associated with Lutetium (177Lu) edotreotide

100 Patents (Medical) associated with Lutetium (177Lu) edotreotide

Literatures (Medical) associated with Lutetium (177Lu) edotreotide

01 Jun 2024·Journal of nuclear medicine : official publication, Society of Nuclear Medicine

Safety and Efficacy ofPara-Aminohippurate Coinfusion for Renal Protection During Peptide Receptor Radiotherapy in Patients with Neuroendocrine Tumors

Article

Author: Jentzen, Walter ; Meckel, Marian ; van Echteld, Cees J A ; Fendler, Wolfgang P ; Himmen, Stephan ; Coelho, Marta ; Fragoso Costa, Pedro ; Sraieb, Miriam ; Herrmann, Ken ; Moraitis, Alexandros ; Kersting, David

Para-aminohippurate, also known as p-aminohippuric acid (PAH), is used clinically to measure effective renal plasma flow. Preclinically, it was shown to reduce ¹⁷⁷Lu-DOTATOC uptake in the kidneys while improving bioavailability compared with amino acid (AA) coinfusion. We report the safety and efficacy of PAH coinfusion during peptide receptor radiotherapy in patients with neuroendocrine tumors. Methods: Twelve patients with metastatic or unresectable gastroenteropancreatic neuroendocrine tumors received ¹⁷⁷Lu-DOTATOC in 33 treatment cycles. Either 8 g of PAH or a mixture of 25 g of arginine and 25 g of lysine were coinfused. Safety was assessed by monitoring laboratory data, including hematologic and renal data, as well as electrolytes obtained before and 24 h after treatment. For radiation dosimetry, whole-body scans were performed at 1, 24, and 48 h and a SPECT/CT scan was performed at 48 h, along with blood sampling at 5 min and 0.5, 2, 4, 24, and 48 h after administration. Absorbed dose estimations for the kidneys and bone marrow were performed according to the MIRD concept. Results: In 15 treatment cycles, PAH was coinfused. No changes in mean creatinine level, glomerular filtration rate, and serum electrolytes were observed before or 24 h after treatment when using PAH protection (P ≥ 0.20), whereas serum chloride and serum phosphate increased significantly under AA (both P < 0.01). Kidney-absorbed dose coefficients were 0.60 ± 0.14 Gy/GBq with PAH and 0.53 ± 0.16 Gy/GBq with AA. Based on extrapolated cumulative kidney-absorbed doses for 4 cycles, 1 patient with PAH protection and 1 patient with AA protection in our patient group would exceed the 23-Gy conservative threshold. The bone marrow-absorbed dose coefficient was 0.012 ± 0.004 Gy/GBq with PAH and 0.012 ± 0.003 Gy/GBq with AA. Conclusion: PAH is a promising alternative to AA for renal protection during peptide receptor radiotherapy. Further research is required to systematically investigate the safety profile and radiation dosimetry at varying PAH plasma concentrations.

01 Jan 2024·Theranostics

Long-term Nephrotoxicity after PRRT: Myth or Reality

Article

Author: Yu, Fei ; Zhang, Jingjing ; Baum, Richard P ; Schuchardt, Christiane ; Fan, Xin ; Chen, Xiaoyuan ; Jakobsson, Vivianne

Rationale: The kidneys are commonly considered as the potential dose-limiting organ for peptide receptor radionuclide therapy (PRRT), making the risk of nephrotoxicity a primary concern. This retrospective analysis with prospective documentation and long-term follow-up aims to assess the risk of nephrotoxicity after PRRT in a large cohort of patients with neuroendocrine neoplasms (NENs) treated at our institution over the past 18 years. Methods: A total of 1361 NEN patients treated with 1-10 cycles of ¹⁷⁷Lu-DOTA-TOC/-NOC/-TATE, ⁹⁰Y-DOTA-TOC/-NOC/-TATE, DUO-PRRT (sequential administration of ⁹⁰Y- and ¹⁷⁷Lu-), or TANDEM-PRRT (combination of ⁹⁰Y- and ¹⁷⁷Lu- on the same day concomitantly) were included in this analysis. All parameters were prospectively documented in a structured database comprising over 250 items per patient and retrospectively analyzed. Kidney function, including serum creatinine, blood urea nitrogen, cGFR, and electrolytes, was evaluated before each PRRT cycle and during follow-up. Restaging was regularly performed at 6-month intervals until death. Treatment-related adverse events were graded according to the Common Terminology Criteria for Adverse Events (CTCAE v.5.0). Results: Between 2000 and 2018, a total of 5409 cycles of PRRT were administered to 1361 NEN patients. Follow-up after complete treatment was available for 1281 patients receiving 4709 cycles of PRRT, with a median follow-up time of 69.2 months (interquartile range, 32.8-110.5 months) and a maximum follow-up time of 175 months. Baseline creatinine levels were normal in 1039/1281 (81.1%) subjects, while grade 1 (G1) renal insufficiency was present in 221/1281 (17.3%) prior to PRRT. G2 was present in 19/1281 (1.5%), and G3 in 2/1281 (0.2%). After treatment, the proportion of G3/G4 grade patients only increased from 0.2% to 0.7%. Mean creatinine levels increased from a baseline of 0.90 ± 0.30 to 1.01 ± 0.57 mg/L (80.0 ± 26.7 to 89.4 ± 50.8 μmol/L) after treatment. In our main analysis cohort of 1244 patients (4576 cycles), 200 patients experienced an increase in CTCAE creatinine grade. Age, number of treatment cycles, type of radionuclides, and length of follow-up time were the main factors affecting CTCAE creatinine grading after treatment. When comparing the subgroups treated with different radionuclides, the risk of nephrotoxicity after ⁹⁰Y treatment alone and the ⁹⁰Y/¹⁷⁷Lu combination group was higher than after ¹⁷⁷Lu treatment alone. In the ⁹⁰Y treatment subgroup, the two significant risk factors for an increased CTCAE creatinine grade were identified to be age (≥60) and a long follow-up time. Conclusions: This retrospective analysis with prospective documentation in a large cohort of 1281 NEN patients receiving 4709 cycles of PRRT co-administered with renal protection, treated through the individualized approach at a single institution over 18 years, did not reveal any evidence of long-term PRRT-related renal toxicity. The results of our study suggest that with the use of proper renal protection, nephrotoxicity due to PRRT is more likely a myth than a reality.

01 Jul 2023·Journal of nuclear medicine : official publication, Society of Nuclear Medicine

¹⁶¹Tb-DOTATOC Production Using a Fully Automated Disposable Cassette System: A First Step Toward the Introduction of ¹⁶¹Tb into the Clinic.

Article

Author: Landolt, Stefan ; van der Meulen, Nicholas P ; Grundler, Pascal V ; Talip, Zeynep ; Sepini, Lebogang ; Köster, Ulli ; Schibli, Roger ; Favaretto, Chiara ; Geistlich, Susanne ; Müller, Cristina

¹⁶¹Tb is an interesting radionuclide for application in the treatment of neuroendocrine neoplasms' small metastases and single cancer cells because of its conversion and Auger-electron emission. Tb has coordination chemistry similar to that of Lu; therefore, like ¹⁷⁷Lu, it can stably radiolabel DOTATOC, one of the leading peptides used for the treatment of neuroendocrine neoplasms. However, ¹⁶¹Tb is a recently developed radionuclide that has not yet been specified for clinical use. Therefore, the aim of the current work was to characterize and specify ¹⁶¹Tb and to develop a protocol for the synthesis and quality control of ¹⁶¹Tb-DOTATOC with a fully automated process conforming to good-manufacturing-practice guidelines, in view of its clinical use. Methods: ¹⁶¹Tb, produced by neutron irradiation of ¹⁶⁰Gd in high-flux reactors followed by radiochemical separation from its target material, was characterized regarding its radionuclidic purity, chemical purity, endotoxin level, and radiochemical purity (RCP) in analogy to what is described in the European Pharmacopoeia for no-carrier-added ¹⁷⁷Lu. In addition, ¹⁶¹Tb was introduced into a fully automated cassette-module synthesis to produce ¹⁶¹Tb-DOTATOC, as used for ¹⁷⁷Lu-DOTATOC. The quality and stability of the produced radiopharmaceutical in terms of identity, RCP, and ethanol and endotoxin content were assessed by means of high-performance liquid chromatography, gas chromatography, and an endotoxin test, respectively. Results: ¹⁶¹Tb produced under the described conditions showed, as the no-carrier-added ¹⁷⁷Lu, a pH of 1-2, radionuclidic purity and RCP of more than 99.9%, and an endotoxin level below the permitted range (175 IU/mL), indicating its appropriate quality for clinical use. In addition, an efficient and robust procedure for the automated production and quality control of ¹⁶¹Tb-DOTATOC with clinically applicable specifications and activity levels, that is, 1.0-7.4 GBq in 20 mL, was developed. The radiopharmaceutical's quality control was also developed using chromatographic methods, which confirmed the product's stability (RCP ≥ 95%) over 24 h. Conclusion: The current study demonstrated that ¹⁶¹Tb has appropriate features for clinical use. The developed synthesis protocol guarantees high yields and safe preparation of injectable ¹⁶¹Tb-DOTATOC. The investigated approach could be translated to other DOTA-derivatized peptides; thus, ¹⁶¹Tb could be successfully applied in clinical practice for radionuclide therapy.

News (Medical) associated with Lutetium (177Lu) edotreotide

28 Jan 2025

·pipelinereview.com

ITM Announces Positive Topline Results of Phase 3 COMPETE Trial with ITM-11, a Targeted Radiopharmaceutical Therapy, in Patients with Grade 1 or Grade 2 Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)

GARCHING / MUNICH, Germany I January 28, 2025 I ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced positive topline results from its Phase 3 COMPETE trial in patients with inoperable, progressive Grade 1 or Grade 2 gastroenteropancreatic neuroendocrine tumors (GEP-NETs). The data showed that ITM-11 (n.c.a. 177 Lu-edotreotide), a proprietary, synthetic, targeted radiotherapeutic agent, met the primary endpoint of prolonging progression-free survival (PFS) when compared to everolimus, a targeted molecular therapy. ITM-11 was well-tolerated with favorable safety results observed. COMPETE is a prospective, randomized, controlled, open-label Phase 3 trial evaluating the efficacy and safety of ITM-11 compared to everolimus, a standard of care treatment. ITM-11 is comprised of non-carrier-added (n.c.a.) lutetium-177, a therapeutic β-emitting radioisotope, and edotreotide, a somatostatin receptor (SSTR) agonist. The trial enrolled 309 patients with Grade 1 or Grade 2 inoperable, progressive, somatostatin receptor-positive neuroendocrine tumors of gastroenteric or pancreatic origin (Ki-67 ≤20%). Patients were randomized 2:1 to receive 7.5 GBq of ITM-11 with a nephroprotective amino acid solution every three months for a maximum of four cycles, or everolimus 10 mg daily for up to 30 months, or until disease progression. The COMPETE trial was conducted at multiple sites throughout the world. “With COMPETE, this marks the first time that a targeted radiopharmaceutical therapy has demonstrated improved progression-free survival compared to a targeted molecular therapy, everolimus, in patients with Grade 1 and Grade 2 gastroenteropancreatic neuroendocrine tumors in a Phase 3 clinical trial. The patients included represent a real-life scenario, and the COMPETE study evaluates the important question of which therapy might be used first to provide greater benefit to patients,” said Jaume Capdevila, MD, PhD, study investigator and senior medical oncologist at Vall d’Hebron University Hospital, Barcelona . “As a clinician, I am highly encouraged by these data and look forward to seeing further results.” “We want to thank the patients, families and caregivers, and investigators for their commitment to and trust in this trial. People with GEP-NETs, whose journey from diagnosis to proper treatment can take years, remain in significant need of more robust, data-driven treatment options to maximize outcomes. The successful COMPETE data support ITM-11’s potential and we believe mark an important milestone for patients and for ITM,” said Dr. Andrew Cavey, CEO of ITM . “Our organization now has demonstrated both early and late-stage clinical development capabilities that complement our leadership in global isotope manufacturing.” Secondary endpoints in the COMPETE trial include objective response rate, overall survival, and quality of life assessments. Additionally, dosimetry was used to assess the absorbed ITM-11 dose in tumors compared to that in healthy tissue to enhance monitoring of the patient’s safety and efficacy. These dosimetry data and secondary endpoints, along with subgroup analyses, are currently being evaluated. The company plans to submit the results for presentation at a future medical meeting and anticipates discussing a potential New Drug Application (NDA) submission with the FDA in 2025. In addition to the COMPETE trial, ITM-11 is being evaluated in a Phase 3 trial (COMPOSE) in patients with well-differentiated, aggressive Grade 2 or Grade 3, SSTR-positive GEP-NET tumors. The COMPOSE trial is a prospective randomized, controlled, open-label trial evaluating the efficacy, safety and patient-reported outcomes of ITM-11 as first or second line treatment compared to physician’s choice standard of care chemotherapy. Additional clinical programs with ITM-11 include a Phase 1 pediatric trial in SSTR-positive tumors (KinLET) and a Phase 3 investigator-sponsored trial in lung and thymus neuroendocrine tumors (LEVEL). About GEP-NETS Neuroendocrine tumors (NETs) are a rare form of cancer, with an estimated 8 new cases per 100,000 individuals diagnosed each year in the U.S. and 9 cases per 100,000 in Europe. The incidence of NETs has steadily increased over recent decades, resulting, in part, from improved diagnosis. Gastroenteropancreatic neuroendocrine tumors (GEP-NETS) originate in the neuroendocrine system, and are made up of nerve cells and hormone-producing cells. They can occur anywhere in the GI tract and pancreas, including the stomach, small intestine, colon, rectum, and appendix. There is still a high unmet medical need for treatment options, as many patients are asymptomatic and diagnosed at a late stage with metastatic disease. About ITM-11 (n.c.a. 177 Lu-edotreotide) ITM-11 is a radiolabeled peptide conjugate that delivers beta radiation specifically to SSTR-positive tumor cells, sparing healthy organs and tissue. ITM-11, delivered intravenously, is comprised of non-carrier-added lutetium-177, a therapeutic β-emitting radioisotope, and edotreotide, a synthetic SSTR agonist. ITM-11 was granted orphan drug designation in the EU and the US, and fast track designation in the US for the treatment of GEP-NETs, based on positive results from a retrospective Phase 2 study 1 with 177 Lu-edotreotide. About ITM Isotope Technologies Munich SE ITM, a leading radiopharmaceutical biotech company, is dedicated to providing a new generation of radiopharmaceutical therapeutics and diagnostics for hard-to-treat tumors. We aim to meet the needs of cancer patients, clinicians and our partners through excellence in development, production and global supply. With improved patient benefit as the driving principle for all we do, ITM advances a broad precision oncology pipeline, including multiple Phase 3 studies, combining the company’s high-quality radioisotopes with a range of targeting molecules. By leveraging our two decades of pioneering radiopharma expertise, central industry position and established global network, ITM strives to provide patients with more effective targeted treatment to improve clinical outcome and quality of life. www.itm-radiopharma.com References: SOURCE: ITM

Clinical ResultPhase 3Fast TrackOrphan DrugPhase 2

28 Jan 2025

·www.fiercebiotech.com

Longtime manufacturer ITM\'s lead radiotherapy outperforms standard of care in phase 3 neuroendocrine tumor trial

German firm ITM Isotope Technologies is ready to take center stage after helping manufacture radiotherapeutics for other biopharmas.\n After 20 years of building radioisotope expertise as a manufacturer and supplier, German firm ITM Isotope Technologies is ready to take center stage with drugs of its own. ITM’s lead radiopharmaceutical outperformed the current standard-of-care treatment at prolonging progression-free survival in a phase 3 trial in patients with inoperable neuroendocrine tumors.ITM endeavors to discuss a new drug application for the candidate, called ITM-11, with the FDA in 2025, the company said in a Jan. 28 release. The company also plans to submit the phase 3 results for presentation at a future medical conference, ITM said.The global phase 3 trial enrolled 309 patients with grade 1 or 2 progressive somatostatin receptor (SSTR)-positive neuroendocrine tumors of gastroenteric or pancreatic origin (GEP-NETs). It compared ITM-11 with targeted molecular therapy everolimus, sold by Novartis as Afinitor for advanced neuroendocrine tumors and other indications.ITM-11 was well tolerated by patients and had favorable safety results, according to the release. ITM did not disclose whether there were adverse events in the trial.The trial’s secondary endpoints of objective response rate, overall survival and quality of life are still being evaluated, ITM said.“People with GEP-NETs, whose journey from diagnosis to proper treatment can take years, remain in significant need of more robust, data-driven treatment options to maximize outcomes,” ITM CEO Andrew Cavey, M.D., said in the release. “Our organization now has demonstrated both early and late-stage clinical development capabilities that complement our leadership in global isotope manufacturing.” That manufacturing leadership includes being the long-term supplier of radioisotope lutetium-177 to Novartis for the creation of metastatic pancreatic cancer drug Pluvicto. Pluvicto is now the most successful radioligand therapy, with sales of $1.04 billion in the first three quarters of 2024.Lutetium-177 is also used in ITM-11, which is delivered intravenously, ITM said.ITM is also testing ITM-11 in multiple other trials, including another phase 3 trial with a different subset of patients with GEP-NETs, those with well-differentiated, aggressive grade 2 or 3 SSTR-positive tumors. A third phase 3 trial is running in patients with lung and thymus neuroendocrine tumors, according to the release, as well as a phase 1 pediatric trial in SSTR-positive tumors.ITM is not putting all of its hopes into one radioactive basket. In addition to ITM-11, the firm has 12 other drug candidates in its pipeline that range in development from preclinical to phase 3.

Phase 3Clinical Result

28 Jan 2025

·endpts.com

ITM aims to compete with Novartis after Phase 3 radiopharma win

ITM Isotope Technologies Munich plans to seek approval for its β-emitting radioligand in gastroenteropancreatic neuroendocrine tumors (GEP-NETs) following a Phase 3 success, the biotech said Tuesday . Treatment with ITM-11 prolonged progression-free survival compared with everolimus, a standard of care for the rare cancer, according to topline data from the COMPETE study. However, another radiotherapy, Novartis’ Lutathera, is already approved in this population and ITM might have a hard time competing with the much larger company. ITM-11 is a somatostatin analog called edotreotide conjugated to lutetium-177. Lutathera is a different somatostatin analog, dotatate, linked to the same isotope. COMPETE is one of two Phase 3 trials of ITM-11. The open-label study recruited 309 patients with inoperable, progressive grade 1 or grade 2 GEP-NETs. The actual PFS figures from the trial have not been released, but if ITM-11 is approved in this setting — and the German biotech intends to file this year — it will compete with Novartis’ product, so it must at least match Lutathera’s performance. Lutathera was approved in second-line GEP-NETs on the strength of a 79% cut in the risk of progression or death versus control. But the control group in that trial received octreotide, not everolimus, so it is hard to know how great a reduction ITM-11 might need to show to have a good shot at approval. ITM-11 was well-tolerated in COMPETE, with “favorable” safety results, ITM said. Secondary endpoints, including objective response rate, overall survival and quality of life measures, are being evaluated. These and the key PFS number could come later this year. A second pivotal trial of ITM-11 in first- or second-line GEP-NETs, COMPOSE, could generate results in 2027. In a trial in the first-line GEP-NETs setting, Lutathera cut the risk of progression or death by 72%.

Phase 3OligonucleotideDrug ApprovalClinical Result

100 Deals associated with Lutetium (177Lu) edotreotide

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
SSTR positive Gastro-Enteropancreatic Neuroendocrine Tumor	Phase 3	CN	ITM Solucin GmbH	11 Feb 2025
SSTR positive Gastro-Enteropancreatic Neuroendocrine Tumor	Phase 3	CN	Grand Pharmaceutical (China) Co., Ltd.	11 Feb 2025
Neuroendocrine neoplasm of lung	Phase 3	FR	Itm Isotope Technologies Munich SE	27 Oct 2023
Neuroendocrine neoplasm of lung	Phase 3	IT	Itm Isotope Technologies Munich SE	27 Oct 2023
Neuroendocrine neoplasm of lung	Phase 3	ES	Itm Isotope Technologies Munich SE	27 Oct 2023
Somatostatin Receptor-Positive Neuroendocrine Tumor	Phase 3	FR	Itm Isotope Technologies Munich SE	27 Oct 2023
Somatostatin Receptor-Positive Neuroendocrine Tumor	Phase 3	IT	Itm Isotope Technologies Munich SE	27 Oct 2023
Somatostatin Receptor-Positive Neuroendocrine Tumor	Phase 3	ES	Itm Isotope Technologies Munich SE	27 Oct 2023
Thymus Neoplasms	Phase 3	FR	Itm Isotope Technologies Munich SE	27 Oct 2023
Thymus Neoplasms	Phase 3	IT	Itm Isotope Technologies Munich SE	27 Oct 2023

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03049189 (COMPETE, Company_Website) Manual	Phase 3	Gastro-Enteropancreatic Neuroendocrine Tumor	309	ITM-11	rcjxmgiyga(djhegbuskr) = ITM-11 demonstrating clinically relevant and statistically significant benefit in PFS compared to everolimus mezpvwyhvt (wlksyajeqt ) Met	Positive	28 Jan 2025
				Everolimus
NCT04194125 (ESMO 12023 \| ESMO 22023) Manual	Phase 2	Neuroendocrine Tumors	21	177Lu DOTATOC+ CAPTEM	mekhhvjcsi(ilfvjhsyjn) = ataznnaasw ovkqkzsabs (maekltioet, 16.0 - NR) View more	Positive	22 Oct 2023
				177Lu DOTATOC+ CAPTEM (panNET)	mekhhvjcsi(ilfvjhsyjn) = xwstkuquwx ovkqkzsabs (maekltioet, 14.0 - NR)
SNMMI2023	Not Applicable	Gastro-Enteropancreatic Neuroendocrine Tumor	-	4 cycles of PRRT	owzllvuoot(wwnvsbswtm) = 27 of these 36 patients (75%; 14 SI-NET; 4 CUP-NET; 9 P-NET) experienced PD in iStaging liiwstabgd (dapbcjdkti ) View more	-	28 Aug 2023
SNMMI2022	Not Applicable	Gastro-Enteropancreatic Neuroendocrine Tumor	-	[177Lu]DOTATOC (GEP-NET patients)	xihgwolphy(zwmfkenahi) = zesekxkbup npffcowhvq (dhunhvjjzh ) View more	-	08 Aug 2022
SNMMI2019	Not Applicable	-	-	Lu-177 DOTA-LM3	kcrynxrdtz(dotffznpzu) = lqfrplpguo kthaqstdaf (basqynradc ) View more	-	21 May 2019
				Lu-177 DOTATOC	kcrynxrdtz(dotffznpzu) = hnqefccwbe kthaqstdaf (basqynradc ) View more
NCT03049189 (COMPETE, ESMO2018)	Phase 3	Gastro-Enteropancreatic Neuroendocrine Tumor	300	Everolimus	xffygpivxu(mlejeuudty) = szxmaiaunc xvyshhwiep (jremsfrwcd )	-	21 Oct 2018

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Lutetium (177Lu) edotreotide

Overview

Basic Info

Structure/Sequence

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation